Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

Similar articles for PubMed (Select 21427395)


Childhood mortality in a cohort treated with mass azithromycin for trachoma.

Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, Gaynor BD, Porco TC, Emerson PM, Lietman TM.

Clin Infect Dis. 2011 Apr 1;52(7):883-8. doi: 10.1093/cid/cir069.


Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial.

Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, Hong KC, Stoller N, Ray KJ, Emerson P, Gaynor BD, Lietman TM.

JAMA. 2009 Sep 2;302(9):962-8. doi: 10.1001/jama.2009.1266.


Risk factors for ocular chlamydia after three mass azithromycin distributions.

Ayele B, Gebre T, Moncada J, House JI, Stoller NE, Zhou Z, Porco TC, Gaynor BD, Emerson PM, Schachter J, Keenan JD.

PLoS Negl Trop Dis. 2011 Dec;5(12):e1441. doi: 10.1371/journal.pntd.0001441. Epub 2011 Dec 13.


Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions.

Biebesheimer JB, House J, Hong KC, Lakew T, Alemayehu W, Zhou Z, Moncada J, Rogér A, Keenan J, Gaynor BD, Schachter J, Lietman TM.

Ophthalmology. 2009 Nov;116(11):2047-50. doi: 10.1016/j.ophtha.2009.04.041. Epub 2009 Sep 10.


Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.

West SK, Munoz B, Mkocha H, Gaydos C, Quinn T.

Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1492-7.


Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial.

House JI, Ayele B, Porco TC, Zhou Z, Hong KC, Gebre T, Ray KJ, Keenan JD, Stoller NE, Whitcher JP, Gaynor BD, Emerson PM, Lietman TM.

Lancet. 2009 Mar 28;373(9669):1111-8. doi: 10.1016/S0140-6736(09)60323-8.


Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial.

Gebre T, Ayele B, Zerihun M, Genet A, Stoller NE, Zhou Z, House JI, Yu SN, Ray KJ, Emerson PM, Keenan JD, Porco TC, Lietman TM, Gaynor BD.

Lancet. 2012 Jan 14;379(9811):143-51. doi: 10.1016/S0140-6736(11)61515-8. Epub 2011 Dec 20.


Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma.

Melese M, Alemayehu W, Lakew T, Yi E, House J, Chidambaram JD, Zhou Z, Cevallos V, Ray K, Hong KC, Porco TC, Phan I, Zaidi A, Gaynor BD, Whitcher JP, Lietman TM.

JAMA. 2008 Feb 20;299(7):778-84. doi: 10.1001/jama.299.7.778.


Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children.

Coles CL, Levens J, Seidman JC, Mkocha H, Munoz B, West S.

Pediatr Infect Dis J. 2012 Apr;31(4):341-6. doi: 10.1097/INF.0b013e31824155c9.


Longitudinal evaluation of three azithromycin distribution strategies for treatment of trachoma in a sub-Saharan African country, Mali.

Schémann JF, Guinot C, Traore L, Zefack G, Dembele M, Diallo I, Traore A, Vinard P, Malvy D.

Acta Trop. 2007 Jan;101(1):40-53. Epub 2006 Dec 16.


Risk factors for active trachoma and Chlamydia trachomatis infection in rural Ethiopia after mass treatment with azithromycin.

Edwards T, Harding-Esch EM, Hailu G, Andreason A, Mabey DC, Todd J, Cumberland P.

Trop Med Int Health. 2008 Apr;13(4):556-65. doi: 10.1111/j.1365-3156.2008.02034.x. Epub 2008 Feb 14.


Reduction and return of infectious trachoma in severely affected communities in Ethiopia.

Lakew T, House J, Hong KC, Yi E, Alemayehu W, Melese M, Zhou Z, Ray K, Chin S, Romero E, Keenan J, Whitcher JP, Gaynor BD, Lietman TM.

PLoS Negl Trop Dis. 2009;3(2):e376. doi: 10.1371/journal.pntd.0000376. Epub 2009 Feb 3.


A rationale for continuing mass antibiotic distributions for trachoma.

Ray KJ, Porco TC, Hong KC, Lee DC, Alemayehu W, Melese M, Lakew T, Yi E, House J, Chidambaram JD, Whitcher JP, Gaynor BD, Lietman TM.

BMC Infect Dis. 2007 Aug 7;7:91.


Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children.

Whitty CJ, Glasgow KW, Sadiq ST, Mabey DC, Bailey R.

Pediatr Infect Dis J. 1999 Nov;18(11):955-8.


Latrine promotion for trachoma: assessment of mortality from a cluster-randomized trial in Ethiopia.

Gebre T, Ayele B, Zerihun M, House JI, Stoller NE, Zhou Z, Ray KJ, Gaynor BD, Porco TC, Emerson PM, Lietman TM, Keenan JD.

Am J Trop Med Hyg. 2011 Sep;85(3):518-23. doi: 10.4269/ajtmh.2011.10-0720.


Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.

West SK, Munoz B, Mkocha H, Holland MJ, Aguirre A, Solomon AW, Foster A, Bailey RL, Mabey DC.

Lancet. 2005 Oct 8;366(9493):1296-300.


Randomised controlled trial of single-dose azithromycin in treatment of trachoma.

Bailey RL, Arullendran P, Whittle HC, Mabey DC.

Lancet. 1993 Aug 21;342(8869):453-6.


Mass treatment with single-dose azithromycin for trachoma.

Solomon AW, Holland MJ, Alexander ND, Massae PA, Aguirre A, Natividad-Sancho A, Molina S, Safari S, Shao JF, Courtright P, Peeling RW, West SK, Bailey RL, Foster A, Mabey DC.

N Engl J Med. 2004 Nov 4;351(19):1962-71.


Community risk factors for ocular Chlamydia infection in Niger: pre-treatment results from a cluster-randomized trachoma trial.

Amza A, Kadri B, Nassirou B, Stoller NE, Yu SN, Zhou Z, Chin S, West SK, Bailey RL, Mabey DC, Keenan JD, Porco TC, Lietman TM, Gaynor BD; PRET Partnership.

PLoS Negl Trop Dis. 2012;6(4):e1586. doi: 10.1371/journal.pntd.0001586. Epub 2012 Apr 24.


Diagnostic characteristics of tests for ocular Chlamydia after mass azithromycin distributions.

Keenan JD, See CW, Moncada J, Ayele B, Gebre T, Stoller NE, McCulloch CE, Porco TC, Gaynor BD, Emerson PM, Schachter J, Lietman TM.

Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):235-40. doi: 10.1167/iovs.11-8493.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk